cc-scope-fit

Scope Fit (cc-scope-fit)

When to trigger

• Starting a project and unsure if Cancer Cell is the right venue
• A reviewer or PI says "this feels incremental" or "too descriptive"
• Considering a Cell Press presubmission inquiry
• Deciding between Cancer Cell and a broader-scope or specialty journal

What Cancer Cell wants

Cancer Cell publishes mechanistic, hypothesis-driven cancer biology and translational oncology. The recurring acceptance pattern combines two pillars:

1. Mechanistic depth — a defined molecular mechanism (a pathway, regulatory axis, genetic/epigenetic event, or cell-cell interaction), not just a phenotype or a correlation.
2. Translational relevance — the mechanism matters for human cancer: it is anchored in patient data, predicts a vulnerability, or motivates a therapeutic / biomarker strategy.

In-scope topics include tumor biology and signaling, cancer genetics / genomics, the tumor microenvironment, immuno-oncology, metastasis, therapy resistance, and clinical-translational studies that carry mechanistic insight.

Fit decision table

| Signal in the manuscript | Fit verdict |

|-----------------------------------------------------------------------|--------------------------------------|

| Clear mechanism + validated in cells, in vivo, AND human/patient data | Strong fit |

| Mechanism + in vivo, human data is associative but supportive | Likely fit — strengthen human anchor |

| Mechanism only in cell lines, no in vivo, no human relevance | Off-fit — go back to cc-study-design |

| Descriptive omics / atlas with no mechanism or vulnerability | Off-fit unless reframed around a mechanism |

| Strong clinical correlation but no mechanism | Off-fit — likely a specialty / clinical journal |

| Methods / tool paper without a cancer-biology discovery | Off-fit — a methods journal |

| Therapeutic claim with only in vitro support | Premature — needs in vivo / human validation |

How to position the contribution

• State the gap in mechanistic understanding, not just "X is understudied."
• Name the orthogonal systems that will close it (cells + in vivo + human).
• Make the translational hook explicit and proportionate to the evidence (mechanism → vulnerability → candidate intervention/biomarker).
• Compare to the closest 2–3 prior papers and say precisely what is new (new mechanism, new node, new context, new in vivo proof).

Presubmission inquiry decision gate

For a borderline paper, reduce the decision to three evidence questions before investing in a full

Cancer Cell package:

| Question | Strong answer | Weak answer |

|----------|---------------|-------------|

| Mechanism | The causal molecular axis is perturbed, rescued, and connected to phenotype. | The axis is inferred from correlation or omics enrichment only. |

| Human anchor | Patient samples, clinical dataset, organoid, or translational model supports relevance. | Only immortalized cell-line evidence or an anecdotal clinical correlation. |

| Therapeutic/biomarker logic | The intervention, vulnerability, or stratification claim follows from the mechanism. | Translational language is aspirational and not tested. |

If one column is weak, the best next move is usually cc-study-design, not cover-letter polish. If all

three are strong, a presubmission inquiry can emphasize the mechanism, the human anchor, and the exact

delta over the nearest Cancer Cell or Cell Press papers.

Checklist

• [ ] One sentence states the mechanism (molecule/axis → effect on cancer phenotype)
• [ ] Mechanism is validated in ≥2 orthogonal systems, ideally including human/patient data
• [ ] Translational relevance is explicit and matched to the evidence level
• [ ] Closest prior work is identified; the advance over it is specific
• [ ] The study is hypothesis-driven, not purely descriptive
• [ ] Therapeutic / biomarker claims are backed by in vivo and/or human data
• [ ] If a clinical-trial-style study, mechanism still carries the novelty

Anti-patterns

• A single-system (cell-line-only) story pitched as a major mechanism
• Descriptive single-cell / genomic atlas with no functional mechanism or vulnerability
• "Therapeutic target" framing with no in vivo efficacy or human evidence
• Overclaiming clinical impact from a correlation
• Repackaging an incremental extension of the lab's prior paper without a new mechanistic node

Output format

【Scope verdict】Strong fit / Likely fit / Off-fit
【Mechanism (1 sentence)】...
【Orthogonal validation present】cells / in vivo / human — list which
【Translational hook】... (and whether evidence supports it)
【Gap vs. closest prior work】...
【Next step】Strengthen via cc-study-design / proceed to cc-study-design / reconsider venue